Durante mucho tiempo no había principios uniformes para la Atribución de nombres a los antibióticos https://antibioticos-wiki.es . Más a menudo se les llama por el nombre genérico o especie del producto, con menos frecuencia-de acuerdo con la estructura química. Algunos antibióticos se nombran de acuerdo con el lugar donde se asignó el producto.
Msci usa imi utilities
The MSCI USA Investable Market Index (IMI) Utilities
is designed to capture the large, mid and small cap
segments of the US equity universe. All securities in the index are classified in the Utilities sector as per the
Global Industry Classification Standard (GICS®).
Cumulative Index Performance — Gross Returns (Feb 1999 – Feb 2014) — USD
Index Performance — Gross Returns (%) (February 28, 2014)
Index Risk and Return Characteristics (February 28, 2014)
2 Based on monthly gross returns data
The MSCI USA IMI Utilities was launched on Jun 05, 2007. Data prior to the launch date is back-tested data (i.e. calculations of how the index might have performed over that time period had the index
existed). There are frequently material differences between back-tested performance and actual results. Past performance -- whether actual or back-tested -- is no indication or guarantee of future
Independent Power Producers & Energy Traders 4.34%
Index MethodologyThe index is based on comprehensive and consistent approach to index constructionthat allows for meaningful global views and cross regional comparisons across all market capitalization size, sector and style segments and combinations.
This methodology aims to provide exhaustive coverage of the relevant investment opportunity set with a strong emphasis on index liquidity, investabilityand replicability. The index is reviewed quarterly—in February, May, August and November—with the objective of reflecting change in the underlying equitymarkets in a timely manner, while limiting undue index turnover. During the May and November semi-annual index reviews, the index is rebalanced andthe large, mid and small capitalization cutoff points are recalculated.
MSCI Inc. is a leading provider of investment decision support tools to investors globally, including asset managers, banks, hedge funds and pension funds. MSCI products and services include indexes, portfolio risk and performance analytics,and governance tools.
The company's flagship product offerings are: the MSCI indexes with approximately USD 7.5 trillion estimated to be benchmarked to them on a worldwide basis1; Barra multi-asset class factor models, portfolio risk and performance analytics;RiskMetrics multi-asset class market and credit risk analytics; IPD real estate information, indexes and analytics; MSCI ESG (environmental, social and governance) Research screening, analysis and ratings; ISS corporate governance research, dataand outsourced proxy voting and reporting services; and FEA valuation models and risk management software for the energy and commodities markets. MSCI is headquartered in New York, with research and commercial offices around the world.1As of March 31, 2013, as reported on July 31, 2013 by eVestment, Lipper and Bloomberg.
The information contained herein (the "Information") may not be reproduced or redisseminated in whole or in part without prior written permission from MSCI. The Information may not be used to verify or correct other data, to create indices, risk
models, or analytics, or in connection with issuing, offering, sponsoring, managing or marketing any securities, portfolios, financial products or other investment vehicles. Historical data and analysis should not be taken as an indication or guarantee of
any future performance, analysis, forecast or prediction. None of the Information or MSCI index or other product or service constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading
strategy. Further, none of the Information or any MSCI index is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. The Information is
provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information. NONE OF MSCI INC. OR ANY OF ITS SUBSIDIARIES OR ITS OR THEIR DIRECT OR INDIRECT SUPPLIERS
OR ANY THIRD PARTY INVOLVED IN THE MAKING OR COMPILING OF THE INFORMATION (EACH, AN "MSCI PARTY") MAKES ANY WARRANTIES OR REPRESENTATIONS AND, TO THE MAXIMUM EXTENT PERMITTED BY LAW, EACH
MSCI PARTY HEREBY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. WITHOUT LIMITING ANY OF THE FOREGOING AND TO
THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL ANY OF THE MSCI PARTIES HAVE ANY LIABILITY REGARDING ANY OF THE INFORMATION FOR ANY DIRECT, INDIRECT, SPECIAL, PUNITIVE, CONSEQUENTIAL
(INCLUDING LOST PROFITS) OR ANY OTHER DAMAGES EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES. The foregoing shall not exclude or limit any liability that may not by applicable law be excluded or limited.
2014 MSCI Inc. All rights reserved.
Best Medicines Coalition National Pharmaceuticals Strategy Issue Paper March 2006 Best Medicines Coalition Tel: 1-888-807-7904 Email: email@example.com Web: www.bestmedicines.ca Healthcare at a Crossroads: BMC Recommendations 16 Appendix I: About Best Medicines Coalition Introduction The positions taken in this Paper and recommendations made are based on the
Original articles in peer reviewed journals 2011 (In Press) Reich K , Schenkel B, Zhao N, Szapary P, Augustin M, Bourcier M, Guenther L, Langley RG. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat. 2010 Oct 31. [Epub in Medline ahead of print] 20